Prevalensi Seropositif Antibodi Anti-rubela pada Mahasiswi Fakultas Kedokteran Universitas Indonesia Jakarta: Upaya untuk Menurunkan Angka Kejadian Sindrom Rubela Kongenital
Sari
Latar belakang. Infeksi rubela pada ibu hamil dapat mengakibatkan komplikasi yang serius pada janin.
Maka remaja perempuan sebagai calon ibu harus telah mempunyai kadar antibodi anti-rubela yang tinggi.
Tujuan. Penelitian ini dilakukan untuk mengetahui prevalensi seropositif terhadap antibodi anti-rubela
pada remaja perempuan sebagai upaya untuk menurunkan angka kejadian sindrom rubela kongenital.
Metode. Penelitian deskriptif potong lintang, dilakukan terhadap 97 orang mahasiswi tingkat I dan II
Fakultas Kedokteran Universitas Indonesia, yang dipilih secara konsekutif pada bulan Mei-Juni 2007.
Hasil. Usia rerata subjek 18,9 tahun (SD=1,0). Imunisasi MMR didapatkan pada 19 dari 97 subjek
penelitian (19,6%). Angka seropositif terhadap antibodi anti-rubela 71 subjek (73,2%) rerata kadar antibodi
anti-rubela 159,7 UI/ml (SD = 107,4). Proporsi seropositif antibodi anti-rubela yang diperoleh melalui
imunisasi MMR 19 dari 71 subjek (26,8%) nilai rerata kadar antibodi anti-rubela 148,9 UI/ml (SD =
86,4). Proporsi seropositif antibodi anti-rubela yang diperoleh melalui infeksi alamiah 52 dari 71 subjek
(73,2%) rerata kadar antibodi anti-rubela 163,6 UI/ml (SD = 114,7).
Kesimpulan. Prevalensi seropositif antibodi anti-rubela 73,2%. Imunitas yang ditimbulkan dengan
pemberian imunisasi MMR sama dengan imunitas yang diperoleh dari infeksi alamiah.
Kata Kunci
Teks Lengkap:
PDFReferensi
Cherry JD. Rubella virus. Dalam: Feigin RD, Cherry
JD, Demmier GJ, Kaplan SL, penyunting. Textbook of
Pediatric Infectious Diseases Volume 2. Edisi ke-5. Philadelphia:
WB Saunders;2004.h.2134-62.
Gershon, AA. Rubella (German Measles). Dalam Katz
SL, Gershon AA, Hotez PJ, penyunting. Krugman’s Infectious
Diseases of Children. Edisi ke-11. Philadelphia:
Mosby;2004.h.531-44.
Plotkin SA, Reef S. Rubella vaccines. Dalam: Plotkin
SA, Orenstein WA, penyunting, Vaccines. Edisi ke-4.
Philadelpia: WB Saunders, 2004. h.707-43.
World Health Organization (WHO). Report of a meeting
on preventing congenital rubella sindrome: immunization
strategies, surveillance needs. Geneva Switzerland:
Department of Vaccines and Biologicals, WHO;
Bin-Su S, Guo HR. Seroprevalence rubella among
women of childbearing age in Taiwan after nationwide
vaccination. Am J Trop Med Hyg 2002; 67: 549-53.
Cutts FT, Robertson SE, Diaz JL, Samuel R. Control of
rubella and congenital rubella syndrome (CRS) in developing
countries. Part 1: Burden of disease from CRS.
Bull World Health Organ 1997;75:55-68.
Robertson SE, Cutt FT, Samuel R, Diaz JL. Control of
rubella and congenital rubella syndrome (CRS) in developing
countries. Part 2: vaccination againts rubella.
Bull World Health Organ 1997;75:69-80.
Tseng HF, Chang CK, Tan HF, Yang SE, Chang HW.
Seroepidemiology study of rubella antibodies among
pregnant women from seven Asian countries: evaluation
of rubella vaccination program in Taiwan. Vaccine
;24:5772-7.
Kremer JR, Scneider F, Muller CP. Waning antibodies
in measles and rubella vaccinees-a longitudinal study.
Vaccine 2006;24:2594-601.
Zanetta DMT, Cabrera EMS, Azevedo RS, Burattini
MN, Massad E. Seroprevalence of rubella antibodies in
State of Sao Paulo, Brazil, 8 years after the introduction
of vaccine. Vaccine 2003;21:3795-800.
King JC, Lichenstein R, Feigelman S, Luna C, Permutt
TJ, Patel J. Measles, Mumps, and Rubella antibodies in
vaccinated Baltimore children. AJDC 1993;147:558-60.
Plotkin SA, Buser F. History of RA 27/3 rubella vaccine.
Rev Infect Dis 1985;suppl 1:S77-S78.
Zisman BR, Bazarsky EB, Skibin A, Tam G, Chamney
S, Belmaker I. Differential immune responses to primary
measles-mumps-rubella vaccination in Israeli children.
Clin Dian Lab Immunol 2004;11:913-8. 39
Gioula G, Mataftsi ED, Daniel SA, Dalaina VK.
Seroepidemiology of rubella in northern Greece. Eur J
Clin Microbiol Infect Dis 2004;23:631-3.
Francis BH, Thomas AK, McCarty CA. The impact of
rubella immunization on the serological status of women
childbearing age: a retrospective longitudinal study in
Melbourne, Australia. Am J of Public Health 2003;
:1274-6.
Zufferey J, Jacquier P, Chappuis S, Spinier O, Hohlfeld
P, Zuber PL, et all. Seroprevalence of rubella among
women of childbearing age in Switzerland. Eur J Clin
Microbiol Infect Dis 1995;14:691-6.
Eisele CJ. Rubella susceptibility in women of childbearing
age. J Obstet Gynecol Neonatal Nurs
;22:260-3.
Onyenekwee CC, Kehinde TA, Ofor US, Arinola OG.
Prevalence of rubella Ig G antibody in women of childbearing
age in Lagos, Nigeria. West Afr J Med
;19:23-6.
Malakmadze N, Zimmerman LA, Uzicanin A,
Shteinke L, Caceres VM, Kasymbekova K.
Development of rubella vaccination strategy:
contribution of a rubella susceptibility study of women
of childbearing age in Kyrgyzstan. Clin Infect Dis
;38:1780-3.
Mossong J, Putz L, Schneider F, Seroprevalence of
measles, mumps and rubella antibodies in Luxembourg:
results from a national cross-sectional study. Epidemiol
Infect 2003;132:11-8.
Lin DB, Chen CJ. Current seroepidemiology of rubella
virus infection among female residents in Taiwan. J Med
Virol 1993;41:174-8.
Vijayalakshmi P, Anuradha R, Prakash K, Narendran K,
Ravindran M, Prajna L, Brown D. Rubella serosurveys at
three Aravind Eye Hospitals in Tamil Nadu, India. Bull
World Health Organ 2004;82:259-64.
Jarour N, Hayajneh WA, Balbeesi A, Otoom H, Al-
Shurman A, Kharabsheh S. Seroprevalence of rubella
among Jordanian women of childbearing age. Vaccine
;30:1-4.
Rajasundari TA, Chandrasekar K, Vijayalakshmi P,
Muthukkaruppan. Immune status of health care personnel
& post vaccination analysis of immunity againts
rubella in an eye hospital. India J med Res 2006;
:553-8.
Dayan GH, Panero MS, Urquiza A, Molina M, Prieto
S, Perego MD. Rubella and measles seroprevalence
among women of childbearing age, Argentina, 2002.
Epidemiol Infect 2005;133:861-9.
Ong SK, The Soey L, Budiono LH, Djojopranoto M,
Kadi J, Kristanto. Presumably congenital rubella
syndrome. Paediatr Indones 1970;10:201-4
Abdoerrachman MH. Pemeriksaan zat anti-rubela pada
ibu hamil di Jakarta. Maj Kedokt Indon 1997;47:142-5.
Johnson CE, Kumar MI, Whitwell JK. Antibody persistence
after primary measles-mumps-rubella vaccine
and response to second dose given at four to six vs eleven
to thirteen years. Pediatr Infect Dis J 1996;15:687-92.
O’Shea S, Woodward S, Best JM. Rubella vaccination:
persistence of antibodies for 10-21 years. Lancet
;2:909-11.
DOI: http://dx.doi.org/10.14238/sp9.3.2007.157-62
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc-sa4.footer##
Email: editorial [at] saripediatri.org
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.